COVID-19 Seasonality India

India has witnessed a gradual uptick in COVID-19 cases since mid-May 2025, with daily reported cases rising to a few hundred. Simultaneously, wastewater surveillance has indicated an increase in SARS-CoV-2 viral load. A similar trend is being observed in other Asian countries, prompting concerns about a potential new variant or resurgence of the virus.

Emerging Seasonal Trends of COVID-19 in India: A Rational Epidemiological Appraisal

Epidemiological Context and Variants

• Current Dominant Variant – JN.1 (Pirola): The JN.1 variant, a sub-lineage of Omicron (BA.1.529), is the dominant strain globally and in India, first detected in Luxembourg in August 2023 and in India since late 2023. It has shown no significant clinical deviation from earlier Omicron sub-lineages.
• Sub-Lineages and Mild Presentation: Sub-lineages like LF.7 and NB.1.8 have emerged from JN.1, but clinical severity remains mild with no surge in hospitalizations or mortality. Thus, no variant of concern has emerged since November 2021.
• Hybrid Immunity and Infection Dynamics: Despite population-level hybrid immunity from vaccines and natural infections, reinfections are possible. However, immunity effectively prevents severe disease, underscoring waning antibodies but robust memory cell responses.

Reasons Behind the Uptick

• Seasonality of Respiratory Viruses: Respiratory viruses, including SARS-CoV-2, exhibit seasonal trends influenced by humidity, temperature, and crowding. Data from India indicate a cyclical surge every 8–10 months since the January 2022 Omicron wave.
• Genomic Instability of RNA Viruses: SARS-CoV-2, being an RNA virus, naturally undergoes frequent mutations, contributing to minor sub-variant emergence. However, these changes have not led to increased virulence or hospitalizations.
• Enhanced Testing and Surveillance Effect: The current surge is partially attributed to increased COVID-19 testing due to regional case upticks in countries like Singapore and Thailand, leading to greater detection rather than an actual surge in symptomatic disease.

Public Health Implications and Response Strategy

• Limited Epidemiological Significance of 'Active Cases': The concept of 'active cases' is outdated, as individuals now become non-infectious within 1–2 days due to existing immunity. Continuing to use this metric distorts the real public health threat.
• Comparative Disease Burden Perspective: COVID-19 causes 200–300 daily cases versus 8,000 TB cases, 900 TB deaths, and air pollution-related respiratory mortality in India. The overall health burden of COVID-19 is currently minor.
• Vaccination Policy and Immunological Adequacy: No additional vaccine dose is recommended, as the population has broad hybrid immunity and no variant of concern necessitates booster campaigns. Focus should shift to preventing comorbidities and vaccinating high-risk groups for other respiratory infections.

Practice Question: